These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 31970760)

  • 21. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
    Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
    Fucà G; Corti F; Ambrosini M; Intini R; Salati M; Fenocchio E; Manca P; Manai C; Daniel F; Raimondi A; Morano F; Corallo S; Prisciandaro M; Spallanzani A; Quarà V; Belli C; Vaiani M; Curigliano G; Cremolini C; De Braud F; Di Bartolomeo M; Zagonel V; Lonardi S; Pietrantonio F
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
    Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
    Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D
    Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
    Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
    Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
    Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
    Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
    Le DT; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Atreya CE; Cui Y; Dai T; Marinello P; Diaz LA; André T
    J Clin Oncol; 2020 Jan; 38(1):11-19. PubMed ID: 31725351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
    Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
    Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
    Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S
    Anticancer Res; 2018 Nov; 38(11):6399-6404. PubMed ID: 30396964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
    Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
    JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
    J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
    Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
    Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of Lynch syndrome, BRAF
    Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
    Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.
    Chong LC; Townsend AR; Young J; Roy A; Piantadosi C; Hardingham JE; Roder D; Karapetis C; Padbury R; Maddern G; Moore J; Price TJ
    Target Oncol; 2019 Feb; 14(1):85-91. PubMed ID: 30659494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
    Fang X; Zhong C; Weng S; Hu H; Wang J; Xiao Q; Wang J; Sun L; Xu D; Liao X; Dong C; Zhang S; Li J; Ding K; Yuan Y
    BMC Cancer; 2023 Jul; 23(1):676. PubMed ID: 37464378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.